Home › NDC Lookup › Ingredients › Chlorhexidine Gluconate › 16571-0111-24
🧴image loading
(from DailyMed)

CHLORHEXIDINE GLUCONATE 40 mg/mL Solution, 237 mL

by Rising Pharma Holdings, Inc. · 237 mL in 1 BOTTLE (16571-111-24)
NDC 16571-0111-24
🏷️ FDA NDC (as labeled) 16571-111-24 billing pads the product segment with a zero
This package
Contains237 mL Cost per mL$0.0285 NADAC Per package$6.75 / 237 ml Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.0453/unit — full pricing hub ↓
Also comes in: 118 ml 16571-0111-12 473 ml 16571-0111-48 946 ml 16571-0111-95
OTC Brand On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Chlorhexidine Gluconate (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Aug 18, 2026 — Cross Contamination with Other Products (Sage Products, LLC) · FDA recall D-0837-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 16571-111-24
Product NDC 16571-111
11-digit billing NDC 16571011124
NCPDP billing unit ML — per mL (volume)
RxCUI 211365
UNII MOR84MUD8E
UPC 0316571111480
Application # NDA019258
SPL Set ID d53a01eb-7213-4f19-b74f-acbf0fd54418
Physiologic effect Decreased Cell Wall Integrity
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-07-26
Route TOPICAL
Dosage form SOLUTION
Substance CHLORHEXIDINE GLUCONATE
GPI-14 92100030102020
GCN Seq No 007254
GCN 30011
HICL code 004297
Ingredient (HICL) Chlorhexidine Gluconate
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5B
Therapeutic class — specific (HIC3) Topical Preparations,Antibacterials
AHFS code 08:30.04.00
AHFS class Amebicides
FDB label name CHLORHEXIDINE 4% LIQUID
FDB brand name Chlorhexidine Gluconate
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 16571-111-24 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 16571-0111-24. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Antiinfectives and antiseptics for local oral treatment class.

Drug family (ATC) Antiinfectives and antiseptics for local oral treatment, Antiinfectives, Biguanides and amidines
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerRising Pharma Holdings, Inc.
Application holderECOLAB INC
FDA applicationNDA019258 (NDA)
Labeler code16571
First marketedJul 2023
Product typeHuman Otc Drug
Portfolio525 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name CHLORHEXIDINE 4% LIQUID Ingredient Chlorhexidine Gluconate
📗 Our plain-language guide HelloPharmacist
  • It's actually a prescription-strength antimicrobial rinse, which is different from over-the-counter mouthwash. Your dentist prescribes it specifically to treat gingivitis — that's...
  • What exactly is chlorhexidine rinse for — is it just like a regular mouthwash?
  • Yes, tooth and surface staining is one of the most common side effects of chlorhexidine oral rinse. It can also increase tartar buildup on your teeth. The good news is that this is...
  • My teeth look like they're staining — is that from the rinse?
📖 Read our full Chlorhexidine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII QWA2IZI6FI
    A surfactant derived from coconut oil, cocamine oxide helps reduce surface tension and improves how ingredients mix together in liquid formulations, enhancing product stability and texture.
  • UNII 92005F972D
    A foaming and thickening agent derived from coconut oil. It's used in liquid medicines to improve texture, help distribute active ingredients evenly, and create a pleasant consistency for easier swallowing or application.
  • UNII R4R8J0Q44B
    Gluconic acid is an organic acid derived from glucose. It functions as a buffer and pH adjuster in medicines, helping maintain the product's acidity or alkalinity for stability and proper absorption.
  • UNII WQ29KQ9POT
    Gluconolactone is a mild organic acid derived from glucose. It functions as a buffer and pH regulator in medicines, helping maintain stable acidity levels and improve product stability.
  • UNII 7Q6P4JN1QT
    Hydroxyethyl cellulose is a plant-derived thickening agent made from cellulose, a natural fiber. In medications, it acts as a binder and thickener to hold ingredients together and control the product's consistency and flow.
  • UNII ND2M416302
    Isopropyl alcohol is a clear liquid solvent derived from petroleum. In medicines, it dissolves active ingredients and other components, helps the product flow smoothly, and aids in sterilization during manufacturing.
  • UNII 6F36Q0I0AC
    PEG-150 distearate is a waxy substance made by combining polyethylene glycol with stearic acid. It acts as an emulsifier and surfactant to help blend water and oil-based ingredients, and may also function as a thickener or lubricant in the formulation.
  • UNII 09179OX7TB
    PEG-75 Lanolin is a waxy substance derived from sheep's wool that has been chemically modified to mix easily with water and oil. It acts as an emulsifier and moisturizer in topical formulations, helping blend different ingredients and soften the skin.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII XPS4174QZJ
    A synthetic compound used as an antimicrobial preservative in topical medicines and personal care products. It helps prevent bacterial and fungal growth, extending the product's shelf life.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

11 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescocamide DEA, cocamine oxide, fragrance, gluconic acid*, gluconolactone*, hydroxyethylcellulose, isopropyl alcohol 4%, PEG-75 lanolin, PEG-150 distearate, propylene glycol, quaternium-60, water *contains one or more of these ingredients

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.029 $6.75 / 237 ml
Medicaid paysCMS SDUD · 12 mo $0.0453 $10.74 / 237 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.031 $0.029
▼ Down 7% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Antiseptic Skin Cleanser 4 g/100mL 70000-0407-01 Cardinal 237 ml $0.025 — FDA listed save 11%
Chlorhexidine Gluconate 40 mg/mLthis 16571-0111-24 Rising 237 ml $0.028 — Availability likely —
Antiseptic Skin Cleanser 4 g/100mL 00116-1061-04 Xttrium 118 ml $0.034 — Availability likely +19%
Antiseptic Skin Cleanser 4 mg/100mL 46122-0137-34 AmerisourceBergen 237 ml $0.037 — Availability likely +29%
Foster and Thrive 4 g/100mL 70677-1221-01 McKesson 237 ml $0.037 — Availability likely +29%
Betasept .04 mg/mL 67618-0200-04 Atlantis 118 ml $0.040 — Availability likely +40%
Cardinal Health 4 g/100mL 00116-0061-04 Xttrium 118 ml — — Discontinued —
Antiseptic Skin Cleanser 4 mg/100mL 00116-0137-34 Xttrium 237 ml — — FDA listed —
Antiseptic Skin Cleanser 4 mg/100mL 00116-0161-08 Xttrium 237 ml — — FDA listed —
Betasept .04 mg/mL 00116-0200-01 Xttrium 3785 ml — — FDA listed —
Antiseptic Skin Cleanser 4 mg/100mL 00116-0401-50 Xttrium 237 ml — — FDA listed —
Antiseptic Skin Cleanser 4 g/100mL 00116-0407-01 Xttrium 237 ml — — FDA listed —
Antiseptic Skin Cleanser 4 g/100mL 00116-0767-08 Xttrium 237 ml — — FDA listed —
CliniClean 4 g/100mL 00116-0901-05 Xttrium 118 ml — — Discontinued —
Dyna-Hex 4 4 g/100mL 00116-1060-18 Xttrium 535 ml — — FDA listed —
Foster and Thrive 4 g/100mL 00116-1221-01 Xttrium 237 ml — — FDA listed —
Bactoshield CHG 40 mg/mL 00116-1344-08 Xttrium 3780 ml — — FDA listed —
Antiseptic Skin Cleanser 4 mg/100mL 00116-3678-07 Xttrium 473 ml — — FDA listed —
Hibiclens 4 g/100mL 00234-0575-40 Molnlycke 118 ml — — FDA listed —
Antiseptic Skin Cleanser 4 mg/100mL 00363-1061-08 Walgreen 237 ml — — FDA listed —
Maxiclens Chlorhexidine Gluconate Liquid Solution, 4% 40 mg/mL 00404-0219-01 Henry 118 ml — — FDA listed —
Maxiclens Chlorhexidine Gluconate Liquid Solution, 4% 40 mg/mL 00404-0220-03 Henry 236 ml — — FDA listed —
Maxiclens Chlorhexidine Gluconate Liquid Solution, 4% 40 mg/mL 00404-0221-04 Henry 473 ml — — FDA listed —
Bactoshield CHG 40 mg/mL 11084-0039-03 SC 118 ml — — FDA listed —
Bactoshield CHG 40 mg/mL 11084-0128-03 SC 118 ml — — FDA listed —
Antiseptic Skin Cleanser 4 g/100mL 11822-0116-05 Rite 237 ml — — FDA listed —
Antiseptic Skin Cleanser 4 g/100mL 11822-0891-02 Rite 532 ml — — FDA listed —
Antiseptic Skin Cleanser 4 mg/100mL 11822-3678-07 Rite 473 ml — — FDA listed —
BD E-Z Scrub 107 40 g/1000mL 17271-0107-03 Becton 18 ml — — FDA listed —
Antiseptic Skin Cleanser 4 mg/100mL 36800-0401-50 Topco 237 ml — — FDA listed —
Halyard Chlorhexidine Gluconate 40 mg/mL 39892-0960-01 Owens 118 ml — — FDA listed —
Halyard Chlorhexidine Gluconate 40 mg/mL 39892-0961-01 Owens 118 ml — — FDA listed —
Antiseptic Skin Cleanser 4 mg/100mL 41250-0162-08 Meijer 237 ml — — Discontinued —
Scrub, Scrub-Stat, Foam Safe, Micro-Guard 40 mg/mL 42939-0125-19 AVA, 946 ml — — FDA listed —
Scrub, Scrub-Stat, Foam Safe, Micro-Guard 40 mg/mL 42939-0128-01 AVA, 118 ml — — FDA listed —
Scrub-Stat 40 mg/mL 47593-0464-11 Ecolab 3780 ml — — FDA listed —
Scrub-Stat 40 mg/mL 47593-0468-21 Ecolab 208000 ml — — Discontinued —
Antiseptic Skin Cleanser 4 g/100mL 59779-0767-08 CVS 237 ml — — FDA listed —
Antiseptic Skin Cleanser 4 mg/100mL 63868-0940-08 Chain 237 ml — — FDA listed —
Antiseptic Skin Cleanser 4 g/100mL 68599-5401-00 McKesson 4 bottles — — FDA listed —
CliniClean 4 g/100mL 69464-0901-05 HR 118 ml — — Discontinued —
Hibiclens 4 g/100mL 76420-0535-08 Asclemed 236 ml — — FDA listed —
Surgical Scrub Brush/Sponge With Nail Cleaner 4% CHG 4 g/100mL 84128-0003-01 Xinxiang 30 patches — — FDA listed —
About this product: this is the brand-name version. Some generic versions are approved by the FDA, but we could not confirm current pharmacy availability from our pricing/market data.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2023
On the market since
Jul 2023
📍
2026
Currently FDA-listed
3 years listed
🔒
·
Generic approved (availability unconfirmed)
see note
🔒Generic approved by FDA, but pharmacy availability is not confirmed

The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 16571-0111-24, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
5.1K
Units reimbursed last 4 qtrs
1.5M
Gross reimbursed last 4 qtrs
$65.7K
Avg / prescription
$12.88
Avg / unit
$0.0453
Latest quarter Q4 2025
1.2KRx
Medicaid pays / mL
$0.0453
gross reimbursed
vs
NADAC / mL
$0.0285
acquisition cost
=
Spread
+$0.0168
+59% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
14% FFS 86% MCO
Fee-for-service · 710 Rx Managed care · 4,395 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 106,222 units · 1,852 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: no data reported NY Vermont: 13,809 units · 2,134 per 100k residents VT New Hampshire: no data reported NH Oregon: 22,425 units · 530 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 41,424 units · 330 per 100k residents IL Indiana: 26,566 units · 387 per 100k residents IN Ohio: 434,004 units · 3,683 per 100k residents OH Pennsylvania: 37,536 units · 290 per 100k residents PA New Jersey: 7,082 units · 76.2 per 100k residents NJ Massachusetts: 314,944 units · 4,499 per 100k residents MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 323,681 units · 7,152 per 100k residents KY West Virginia: no data reported WV Virginia: 35,175 units · 404 per 100k residents VA Maryland: 8,034 units · 130 per 100k residents MD Connecticut: no data reported CT Rhode Island: 18,528 units · 1,692 per 100k residents RI Arizona: 11,094 units · 149 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: 40,487 units · 754 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: 10,625 units · 1,565 per 100k residents DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
76.27,152
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 7,152 /100k
2 Massachusetts 4,499 /100k
3 Ohio 3,683 /100k
4 Vermont 2,134 /100k
5 Minnesota 1,852 /100k
6 Rhode Island 1,692 /100k
7 D.C. 1,565 /100k
8 South Carolina 754 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
118 ml16571-0111-12 5,867 Rx · $61,117
237 ml this page16571-0111-24 5,105 Rx · $65,747
473 ml16571-0111-48 4,663 Rx · $75,999
946 ml16571-0111-95 No Medicaid data
Drug total (last 4 qtrs): 15,635 Rx · 5,148,722 units · $202,863 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Chlorhexidine Gluconate — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Chlorhexidine Gluconate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$3.96M
Claims incl. refills
658.9K
Beneficiaries
540.1K
Spend / beneficiary
$7.34
Spend / claim
$6.02
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Chlorhexidine Gluconate — the ingredient across all brands.

Top reported reactions

Fatigue2,139
Rash1,979
Pain1,957
Joint Swelling1,929
Hypersensitivity1,801
Impaired Healing1,786
Folliculitis1,759

Reporter sex

0 reports

Serious outcomes

Death2,815
Disabling2,791
Life-threatening2,632
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 880 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
16571-0111-12 118 mL in 1 BOTTLE (16571-111-12) $0.0399 / mL $4.71 2023-07-26 Active
16571-0111-24 You're viewing this 237 mL in 1 BOTTLE (16571-111-24) $0.0285 / mL $6.75 2023-07-26 Active
16571-0111-48 473 mL in 1 BOTTLE (16571-111-48) $0.0178 / mL $8.40 2023-07-26 Active
16571-0111-95 946 mL in 1 BOTTLE (16571-111-95) — — 2023-07-26 Active

You're viewing one of 4 pack sizes for this product.

Per mL, this pack runs about 60% above the cheapest pack (473 mL, $0.0178 vs $0.0285 NADAC).

This pack accounts for about 33% of this product's recent Medicaid fills; the largest share goes to the 118 ml pack. See all packs ↓

Pack size FAQ

What quantity is in NDC 16571-0111-24?
NDC 16571-0111-24 contains 237 mL — 237 ml in 1 bottle.
What is the difference between NDC 16571-0111-24 and NDC 16571-0111-12?
Both are CHLORHEXIDINE GLUCONATE 40 mg/mL Solution — the drug itself is identical. NDC 16571-0111-24 is the 237 mL package, while NDC 16571-0111-12 is the 118 ml package. Per-mL NADAC also differs: $0.0285 here vs $0.0399 for the 118 ml pack.
What NDC number is used to bill for this package of CHLORHEXIDINE GLUCONATE 40 mg/mL Solution?
Bill NDC 16571-0111-24 — the 11-digit billing format is 16571011124. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose
🎯 Indications and Usage 46 words ▾

Uses surgical hand scrub: significantly reduces the number of microorganisms on the hands and forearms prior to surgery or patient care healthcare personnel handwash: handwash to help reduce bacteria that potentially can cause disease skin wound and general skin cleanser: helps reduce bacteria on the skin

⏱️ Dosage and Administration 154 words ▾

Directions use with care in premature infants or infants under 2 months of age. These product may cause irritation or chemical burns. use full strength do not dilute Surgical hand scrub: remove jewelry wet hands and forearms with water and apply 5 mL of the product wash/scrub hands and forearms for 3 minutes paying particular attention to the nails, cuticles, and interdigital spaces rinse thoroughly with water wash for an additional 3 minutes with 5 mL of the product and rinse under running water dry thoroughly Healthcare personnel handwash: wet hands with water dispense about 5 mL of product into cupped hands and wash in a vigorous manner for 30 seconds rinse and dry thoroughly Skin wound and general skin cleanser: thoroughly rinse the area to be cleansed with water apply the minimum amount of product necessary to cover the skin or wound area and wash gently.

Rinse thoroughly with water. rinse again thoroughly

⚠️ Warnings 214 words ▾

Warnings For external use only Allergy Alert This product may cause a severe allergic reaction. Symptoms may include: wheezing/difficulty breathing shock facial swelling hives rash If an allergic reaction occurs, stop use and seek medical help right away. Do not use if you are allergic to chlorhexidine gluconate or any other ingredients in this preparation as a patient properative skin preparation (especially on the head or face) in contact with meninges in the genital area When using this product keep out of eyes, ears, and mouth.

May cause serious and permanent eye injury if placed or kept in the eye during surgical procedures or may cause deafness when instilled in the middle ear through perforated ear drums if contact occurs, rinse with cold water right away wounds which involve more than the superficial layers of the skin should not be routinely treated repeated general skin cleansing of large body areas should not be done except when underlying condition makes it necessary to reduce the bacterial population of the skin Stop use and ask a doctor if irritation, sensitization, or allergic reaction occurs and lasts for 72 hours.

These may be signs of a serious condition. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 6 words ▾

Active ingredients Chlorhexidine gluconate solution, 4%

🧪 Inactive Ingredients 30 words ▾

Inactive ingredients cocamide DEA, cocamine oxide, fragrance, gluconic acid *, gluconolactone*, hydroxyethylcellulose, isopropyl alcohol 4%, PEG-75 lanolin, PEG-150 distearate, propylene glycol, quaternium-60, water *contains one or more of these ingredients

🎯 Purpose 13 words ▾

Purposes Surgical hand scrub Healthcare personnel handwash Skin wound and general skin cleanser

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 16571-0110-01 · Rising 16571-0112-01 · Rising →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.